Welcome to our dedicated page for Endo news (Ticker: NDOI), a resource for investors and traders seeking the latest updates and insights on Endo stock.
Endo, Inc. (OTCQX: NDOI) is a diversified specialty pharmaceutical company whose news flow spans product launches, clinical research updates, financial results and major corporate transactions. As a participant in the Drug Manufacturers – Specialty & Generic industry, Endo issues frequent press releases on branded therapies, sterile injectables, generics and strategic initiatives.
Investors and healthcare professionals following NDOI news can see updates on clinical development programs, such as Phase 1, Phase 2 and Phase 3 studies of collagenase clostridium histolyticum in plantar fibromatosis and plantar fasciitis, as well as retrospective analyses of patient experiences. Endo also reports on educational initiatives like its Spatial Computing Injection Simulator for Peyronie’s disease, which supports appropriate use of XIAFLEX, the only FDA‑approved nonsurgical treatment for that condition.
Endo’s news feed also features product and portfolio announcements, including expansions of its ADRENALIN epinephrine premixed IV bag line within the Endo Injectable Solutions TruDelivery platform. These releases often include detailed prescribing and safety information relevant to hospital pharmacists and clinicians.
From a capital markets perspective, NDOI news includes quarterly financial results, segment performance commentary across Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals and International Pharmaceuticals, and reaffirmations or updates to financial guidance. In addition, Endo provides regular updates on its proposed combination with Mallinckrodt plc, shareholder approvals, court rulings and the planned separation of the combined generics and sterile injectables business into an entity intended to be called Par Health.
This page aggregates these company‑issued updates so readers can review Endo’s latest disclosures on products, pipelines, financial performance and corporate transactions in one place.
Endo USA, Inc., a subsidiary of Endo, Inc (OTCQX: NDOI), has issued a voluntary nationwide recall of one lot of Clonazepam Orally Disintegrating Tablets, USP (C-IV) due to mislabeling. The recall affects lot number 550147301, where some cartons incorrectly show the strength as 0.125 mg instead of 0.25 mg. This error poses potential risks, including significant sedation, dizziness, and respiratory depression.
The affected product was distributed to retail pharmacies nationwide. Endo is notifying wholesalers and retailers, arranging for the return of existing inventory. Consumers are advised to discontinue use of the product and consult a physician if they inadvertently took a higher dose. No adverse events have been reported to date.
Endo (OTCQX: NDOI) has launched tiopronin delayed-release tablets, a generic version of Travere Therapeutics' THIOLA EC®. This medication is used to prevent cystine kidney stones in certain adult and pediatric patients. Endo is offering copay assistance for eligible patients. The launch strengthens Endo's generic product portfolio and reinforces its position as a reliable supplier.
The drug is indicated for use in combination with high fluid intake, alkali, and dietary changes. It is approved for adults and children 9 years and older with severe homozygous cystinuria who don't respond to other measures alone. Key safety information includes contraindications for hypersensitivity, warnings about proteinuria, and common adverse reactions such as nausea and rash.
Endo, a specialty pharmaceutical company, has filed a registration statement on Form S-1 with the SEC to register certain shares of common stock held by current shareholders. The company emphasizes there will be no new shares issued or sold, and the total number of outstanding shares remains unchanged. The registration statement is part of Endo's strategy to list its common stock on the NYSE, expected later in 2024, pending SEC approval and other customary conditions. Currently, Endo's stock trades on the OTCQX® Best Market, where U.S. investors can access financial disclosures and trading statistics. This release does not constitute an offer to sell or buy securities.
Endo announced the commencement of trading on the OTCQX Best Market under the ticker symbol NDOI. The move signals Endo's commitment to maintaining its public company status and enhancing shareholder value. According to CEO Blaise Coleman, this step aligns with Endo's strategic priorities. The OTCQX Market, known for its stringent financial and governance standards, offers a convenient trading platform for U.S. investors. Endo is also working towards listing on the New York Stock Exchange (NYSE) later in 2024, subject to regulatory approvals and conditions.